A domestic study is drawing attention, showing Janssen’s multiple myeloma treatment Darzalex (daratumumab) marked significant clinical improvement in combined therapy of vortezomib+thalidomide+dexa...
Objective To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. Patients and Methods We studied 16 patients (m...
Summary. To assess the role of the cytokine interleukin 2 (IL2) in the treatment of patients with multiple myeloma, we examined the sensitivity of plasma cell lines and malignant plasma cells from...
Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are av...
More than 150 years have passed since the first treatments of multiple myeloma were initiated. The past decade has seen a renaissance in the generation of therapies for myeloma as a result of heigh...
Multiple myeloma is the second most common type of blood cancer after leukemia. Learn more about the symptoms, causes, diagnosis, risk factors, and treatment of multiple myeloma.
21 Division of Cancer Medicine, Department of Lymphoma/Myeloma, MD Anderson Cancer Center... choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as...
Treatment of Multiple Myeloma and Related Disorders - October 2008
Division of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang... College of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea Tel: +82-2-709-9034, Fax: +82-2...
Treatment of Multiple Myeloma and Related Disorders - October 2008